Shares of BIOCYTOGEN-B (02315) surged more than 6% in Hong Kong trading, with the stock up 6.24% to HK$59.60 at the time of writing, on a turnover of HK$87.29 million.

In the first half of this year, BIOCYTOGEN-B reported revenue of RMB 940 million, a 51.6% increase year-on-year, while net profit attributable to shareholders jumped 402% to RMB 240 million. During the reporting period, the preclinical segment generated total revenue of RMB 723 million, up 57.9% year-on-year, with innovative animal model sales reaching RMB 446 million, a 62.4% increase, and preclinical pharmacology and efficacy evaluation revenue rising 57.0% to RMB 243 million.

Additionally, earlier this month, BIOCYTOGEN-B announced a non-exclusive licensing partnership with Qilu Pharmaceutical for fully human nanobody molecules to support the development of innovative drugs targeting neurological disorders.

Industry outlook and strategic positioning

China Post Securities noted that sustained industry prosperity, coupled with overseas expansion, continues to drive strong growth in the animal model and preclinical efficacy business. Shanghai Shenwan Hongyuan believes the company has established a dual-engine core business axis—combining model animals with its "Thousand Mice, Ten Thousand Antibodies" platform—while deeply penetrating both domestic and international markets. With its closed-loop technology, data barriers, global footprint, and AI-enhanced capabilities, the company is well-positioned to evolve into a globally leading platform for innovative antibody drug discovery.